Innovative Therapy Prapela specializes in noninvasive stimulation therapy based on Stochastic Resonance, targeting improvements in neonatal breathing and lung function. This unique approach presents opportunities to collaborate with neonatal intensive care units and hospitals seeking advanced, science-backed respiratory solutions.

Regulatory Achievements The company has received Breakthrough Device Designation from the FDA, highlighting its potential to significantly advance neonatal care technologies. This status can facilitate faster adoption and open doors to government-funded pilot programs and clinics looking for cutting-edge medical devices.

Market Expansion Recent product launches like the Prapela SVS baby box demonstrate a move into supportive neonatal products for comfort and safe sleep, expanding the company's product portfolio and market reach into neonatal care and parental support markets.

Funding & Growth Potential With over $8 million in awards and grants for clinical evaluation, Prapela is well-positioned to seek strategic partnerships and investment opportunities to accelerate product development, clinical trials, and commercial deployment in pediatric and neonatal markets.

Target Customer Base The company's focus on newborns, preterm infants, and opioid-exposed neonates, combined with its small team size, indicates opportunities to collaborate with neonatal hospitals, healthcare providers, and medical device distributors looking for innovative solutions to improve neonatal respiratory outcomes.